[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 37 of about 37
1. Teske E, van Straten G, van Noort R, Rutteman GR: Chemotherapy with cyclophosphamide, vincristine, and prednisolone (COP) in cats with malignant lymphoma: new results with an old protocol. J Vet Intern Med; 2002 Mar-Apr;16(2):179-86
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy with cyclophosphamide, vincristine, and prednisolone (COP) in cats with malignant lymphoma: new results with an old protocol.
  • This retrospective study in 61 cats with malignant lymphomas examined the efficacy of a well-established chemotherapy protocol (cyclophosphamide, vincristine, and prednisolone [COP]) in the Netherlands, a country with a low prevalence of feline leukemia virus (FeLV).
  • Twenty-two cats (36.1%) had mediastinal lymphoma, 11 (18.0%) had alimentary lymphoma, 7 (11.5%) had peripheral lymphoma, 8 (13.1%) had nasal lymphoma, and 13 (21.3%) had miscellaneous lymphoma (including renal lymphoma in 2 [3.3%]).
  • The median survival time and the 1-year survival rate for mediastinal lymphoma were 262 days and 49.4%. respectively.
  • Response to therapy in this study was shown to be a significant prognostic indicator.
  • Young Siamese cats in this study had a greater tendency to develop mediastinal malignant lymphoma at a young age, and all were FeLV negative.
  • In comparison with results reported in other studies with different combination chemotherapy protocols, these are among the highest percentages of remission and the longest survival rates for cats with malignant lymphoma.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11899035.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


2. Brink I, Reinhardt MJ, Hoegerle S, Altehoefer C, Moser E, Nitzsche EU: Increased metabolic activity in the thymus gland studied with 18F-FDG PET: age dependency and frequency after chemotherapy. J Nucl Med; 2001 Apr;42(4):591-5
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased metabolic activity in the thymus gland studied with 18F-FDG PET: age dependency and frequency after chemotherapy.
  • This study was designed to evaluate the age dependency of 18F-FDG uptake in the thymus and the frequency of PET confirmation of thymus hyperplasia after chemotherapy in cancer patients.
  • METHODS: Whole-body FDG PET recordings of 168 patients were retrospectively examined for a retrosternal lesion in the anterior mediastinum that was attributable to the thymus.
  • The patients were assigned to the following four groups: children with malignant lesions before the first therapy (group Ia; n = 15; mean age +/- SD, 11.9 +/- 3.7 y), children with malignant disease after chemotherapy (group Ib; n = 12; mean age, 10.3 +/- 5.0 y), adults with histologically confirmed malignant lymphoma before the first therapy (group IIa; n = 37; mean age, 43.9 +/- 16.7 y), and adult lymphoma patients 3 wk to 4 mo after chemotherapy (group IIb; n = 104; mean age, 40.9 +/- 14.6 y).
  • CONCLUSION: FDG accumulation in the thymus is a common finding in children and can occasionally be observed in young adults after chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Fluorodeoxyglucose F18. Radiopharmaceuticals. Thymus Gland / radionuclide imaging. Thymus Hyperplasia / chemically induced. Tomography, Emission-Computed
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Diagnosis, Differential. Humans. Lymphoma / drug therapy. Lymphoma / radionuclide imaging. Middle Aged. Neoplasms / drug therapy. Retrospective Studies. Thymus Neoplasms / radionuclide imaging. Thymus Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11337547.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


3. Ozer N, Deveci OS, Kaya EB, Demircin M: Mediastinal lymphoma causing extrinsic pulmonary stenosis. Turk Kardiyol Dern Ars; 2009 Sep;37(6):421-4
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal lymphoma causing extrinsic pulmonary stenosis.
  • A 20-year-old female was referred to our center with a cystic mass detected by transthoracic echocardiography and thoracic computed tomography, in the superoanterior mediastinum, 5.5 x 5.5 x 7 cm in size, causing main pulmonary trunk compression.
  • The pathological diagnosis of the mass was stage IIa nodular sclerosing Hodgkin's lymphoma.
  • The patient received postoperative chemotherapy and thoracal radiotherapy.
  • [MeSH-major] Lymphoma / complications. Mediastinal Neoplasms / complications. Pulmonary Valve Stenosis / etiology
  • [MeSH-minor] Echocardiography, Transesophageal. Female. Humans. Pulmonary Artery / surgery. Pulmonary Artery / ultrasonography. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20019459.001).
  • [ISSN] 1016-5169
  • [Journal-full-title] Türk Kardiyoloji Derneği arşivi : Türk Kardiyoloji Derneğinin yayın organıdır
  • [ISO-abbreviation] Turk Kardiyol Dern Ars
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


Advertisement
4. Zhen ZJ, Sun XF, Xia Y, Wang ZH, Ling JY: [Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma]. Ai Zheng; 2006 Apr;25(4):471-5
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma].
  • BACKGROUND & OBJECTIVE: Reactive thymic hyperplasia following chemotherapy for malignant tumors is likely to be misdiagnosed as tumor residue or relapse, therefore, leads to unnecessary treatment.
  • This study was to analyze the clinical features of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma.
  • METHODS: Clinical data of 13 children with reactive thymic hyperplasia following chemotherapy for malignant lymphoma, treated from Mar.
  • Of the 13 cases, 5 were Hodgkin's disease (HD), and 8 were non-Hodgkin's lymphoma (NHL).
  • All patients received computed tomography (CT) to evaluate the therapeutic effect.
  • When a new thymic mass emerged, positive electron tomography/computed tomography (PET/CT) was performed to identify its quality.
  • RESULTS: At diagnosis, 10 patients had mediastinal involvement.
  • Reactive thymic hyperplasia occurred following the completion of chemotherapy in 9 cases, or during the maintenance of chemotherapy in 4 cases.
  • CT showed that the longest diameters of the new mediastinal masses were 2.2-6.0 cm (mean 3.7 cm).
  • The interval from last chemotherapy cycle to the occurrence of thymic hyperplasia was 2-12 months (mean 4 months).
  • PET/CT was performed to 5 cases, and showed no vital tumors in the mediastinum.
  • Three cases were misdiagnosed as tumor residue or relapse, and received second-line therapy.
  • CONCLUSIONS: Reactive thymic hyperplasia may occur following intensive chemotherapy for childhood malignant lymphoma.
  • It should not be misdiagnosed as malignant tumors and overtreated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Mediastinal Neoplasms / drug therapy. Thymus Hyperplasia / chemically induced
  • [MeSH-minor] Adolescent. Bleomycin / adverse effects. Bleomycin / therapeutic use. Child. Child, Preschool. Dacarbazine / adverse effects. Dacarbazine / therapeutic use. Disease-Free Survival. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Ifosfamide / therapeutic use. Male. Mechlorethamine / adverse effects. Mechlorethamine / therapeutic use. Positron-Emission Tomography. Prednisone / adverse effects. Prednisone / therapeutic use. Procarbazine / adverse effects. Procarbazine / therapeutic use. Tomography, X-Ray Computed. Vinblastine / adverse effects. Vinblastine / therapeutic use. Vincristine / adverse effects. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Thymic hyperplasia.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613683.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide; VB0R961HZT / Prednisone; ABVD protocol; IE protocol; MOPP protocol
  •  go-up   go-down


5. Kaul P, Javangula K: Burkitt lymphoma masquerading as cardiac tamponade. J Cardiothorac Surg; 2007;2:30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma masquerading as cardiac tamponade.
  • A 61 year old man presented with diffuse large B cell lymphoma of the skin of the back of the shoulder which was excised and treated with chemotherapy (CHOP regime) in 1998.
  • He was in complete remission till he presented in 2002 with extranodal marginal zone lymphoma of the parotid gland for which he underwent superficial parotidectomy and radiotherapy.
  • Histology, immunocytochemistry and chromosome analysis revealed Burkitt lymphoma.
  • Patient underwent chemotherapy with CODOX-M regime and continues in remission.
  • This report is unusual on account of the highly atypical presentation of Burkitt lymphoma as cardiac tamponade, only a few cases having been reported previously, the occurrence of three lymphomas of different pathological and genomic profiles in one patient over a period of eight years and the relatively slow rate of growth of an otherwise fulminant tumour with high tumour doubling time.
  • A review of literature with special emphasis on chromosomal diagnosis, transformation of other lymphomas into Burkitt lymphoma and mediastinal and cardiac involvement with Burkitt lymphoma is presented.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Cardiac Tamponade / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Coll Physicians Surg Pak. 2006 Aug;16(8):536-7 [16899184.001]
  • [Cites] Indian J Med Sci. 2006 Sep;60(9):380-4 [16940688.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):687-91 [11340573.001]
  • [Cites] Z Kardiol. 2002 Apr;91(4):347-51 [12063708.001]
  • [Cites] Mod Pathol. 2002 Jul;15(7):771-6 [12118116.001]
  • [Cites] Virchows Arch. 2002 Nov;441(5):456-61 [12447675.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Feb;141(1):86-8 [12581905.001]
  • [Cites] J Am Soc Echocardiogr. 2003 Dec;16(12):1326-30 [14652615.001]
  • [Cites] Int J Cancer. 1980 Jun 15;25(6):711-9 [14768699.001]
  • [Cites] Leuk Res. 2006 Nov;30(11):1417-23 [16697040.001]
  • [Cites] Cytopathology. 1990;1(4):239-42 [2101671.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1748-55 [7564520.001]
  • [Cites] Rinsho Ketsueki. 1997 Sep;38(9):757-62 [9364867.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):121-4 [15613866.001]
  • [Cites] Hum Pathol. 2005 May;36(5):571-5 [15948125.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):294-301 [16848772.001]
  • [Cites] Genes Chromosomes Cancer. 2004 May;40(1):10-8 [15034863.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Oct;41(2):178-82 [15287031.001]
  • [Cites] Ann Surg. 1982 Jul;196(1):82-6 [7092357.001]
  • [Cites] Cancer Genet Cytogenet. 1987 Dec;29(2):245-51 [3677046.001]
  • [Cites] Conn Med. 1990 Apr;54(4):186-9 [2347184.001]
  • [Cites] Rinsho Ketsueki. 1990 Oct;31(10):1731-5 [2255064.001]
  • [Cites] Cancer. 2006 Sep 1;107(5):1084-92 [16862570.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3707-21 [11054444.001]
  • (PMID = 17615068.001).
  • [ISSN] 1749-8090
  • [Journal-full-title] Journal of cardiothoracic surgery
  • [ISO-abbreviation] J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1934902
  • [General-notes] NLM/ Original DateCompleted: 20070810
  •  go-up   go-down


6. Ruiz-Hernández G, Scaglione C, Delgado-Bolton RC, Gutiérrez-García A, Madero L, Jiménez-Vicioso A, Carreras-Delgado JL: [Splenic and bone marrow increased 18F-FDG uptake in a PET scan performed following treatment with G-CSF]. Rev Esp Med Nucl; 2004 Mar-Apr;23(2):124-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Splenic and bone marrow increased 18F-FDG uptake in a PET scan performed following treatment with G-CSF].
  • The thoracic CT showed a bulky mediastinal mass that occupied the pretracheal, paratracheal and right prevascular regions.
  • Biopsy of the mediastinal mass revealed the presence of diffuse large B-cell non-Hodgkin's lymphoma.
  • Treatment included 4 cycles of chemotherapy followed by 7 days of subcutaneous granulocyte colony-stimulating factor (G-CSF, Lenogastrim) at a dose of 5 mg/Kg/day.
  • Following treatment, a CT scan was performed to evaluate response, finding a calcification of the mass without significant reduction of the overall size.
  • Because CT was inconclusive in the assessment of response to therapy, a 18F-FDG PET scan was performed.
  • The 18F-FDG PET scan did not show any pathological uptake in the mediastinum but revealed a splenic and bone marrow diffusely increased 18F-FDG uptake.
  • The differential diagnosis included a secondary effect induced by G-CSF therapy as one of the main possibilities, but other possibilities such as a malignant infiltration by lymphoma could not be discarded.
  • We consider that the stimulating effect that G-CSF therapy has on the spleen and bone marrow must be taken into account when performing a 18F-FDG PET scan, as it can be an important source of false-positive results.
  • [MeSH-major] Bone Marrow / metabolism. Bone Marrow / radionuclide imaging. Fluorodeoxyglucose F18 / metabolism. Granulocyte Colony-Stimulating Factor / adverse effects. Radiopharmaceuticals / metabolism. Spleen / metabolism. Spleen / radionuclide imaging. Tomography, Emission-Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15000944.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


7. Yamauchi K, Yasuda M: Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature. Cancer; 2002 Mar 15;94(6):1739-46
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison in treatments of nonleukemic granulocytic sarcoma: report of two cases and a review of 72 cases in the literature.
  • BACKGROUND: The purpose of this study was to reveal the clinical characteristics of nonleukemic granulocytic sarcoma (GS) and an association between the therapeutic regimens and the nonleukemic period.
  • These patients were divided into 3 groups by therapeutic regimens; Group I included 12 patients who received only biopsy or surgical resection of the tumor, Group II was 20 patients who received local irradiation for the tumor, and Group III consisted of 42 patients who received systemic chemotherapy.
  • In Group III, the period in the patients who were treated with chemotherapy given to ANLL was compared with that in the patients who received chemotherapy used for malignant lymphoproliferative disorders (MLPDs).
  • RESULTS: Thirty-five patients (47%) initially were misdiagnosed, and the disease was most often malignant lymphoma.
  • Preferential sites of GS were the small intestine, mediastinum, epidural site, uterus, and ovary, which often are difficult for the detection and diagnosis in addition to the skin and lymph nodes known commonly.
  • The nonleukemic period after the diagnosis of GS was significantly longer in Group III than in the other groups (median, 12 months in Group III vs. 3 and 6 months in Groups I and II, respectively).
  • The aggressive chemotherapy given to ANLL led to a longer nonleukemic period than the chemotherapy used for MLPDs.
  • CONCLUSIONS: To reduce the risk of subsequent ANLL in patients with nonleukemic GS, it is important that accurate histologic diagnosis is established initially for GS and that all isolated cases of GS, even those that appear to be cured by resection or irradiation of the tumor, are treated with intensive chemotherapy similar to that used to treat ANLL during the nonleukemic period as soon as possible.
  • [MeSH-major] Leukemia, Myeloid, Acute / etiology. Sarcoma, Myeloid / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Humans. Lymphoma / diagnosis. Male. Middle Aged. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 11920536.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 59
  •  go-up   go-down


8. Algalarrondo V, Misra SC, Bennani SL, Mabille M, Cavailloles F, Machover D, Slama MS: Ventricular tachycardia reveals cardiac infiltration due to mediastinal lymphoma. Europace; 2010 Sep;12(9):1344-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ventricular tachycardia reveals cardiac infiltration due to mediastinal lymphoma.
  • After being treated by chemotherapy for a mediastinum lymphoplasmocytic lymphoma, a ventricular tachycardia (VT) occurred.
  • Several imaging techniques showed that this VT was related to a tumoural infiltration of the anterior part of the right ventricle by the lymphoma.
  • Ventricular arrhythmias were controlled under antiarrhythmic drugs and chemotherapy was continued, with close cardiac follow-up.
  • [MeSH-major] Mediastinal Neoplasms / pathology. Waldenstrom Macroglobulinemia / pathology
  • [MeSH-minor] Bundle-Branch Block / etiology. Electrocardiography. Heart Ventricles / pathology. Humans. Male. Middle Aged. Neoplasm Invasiveness. Positron-Emission Tomography. Recurrence. Tachycardia, Ventricular / diagnosis. Tachycardia, Ventricular / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20484340.001).
  • [ISSN] 1532-2092
  • [Journal-full-title] Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
  • [ISO-abbreviation] Europace
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Ratei R, Matylis A, Krahl D, Arnold R, Stein H, Dörken B, Ludwig WD: Salvage therapy for relapsed mediastinal B-cell lymphoma with allogeneic HLA-identical related donor bone marrow transplantation, donor lymphocyte infusion and IDEC-C2B8. Leuk Lymphoma; 2000 Dec;40(1-2):133-40
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage therapy for relapsed mediastinal B-cell lymphoma with allogeneic HLA-identical related donor bone marrow transplantation, donor lymphocyte infusion and IDEC-C2B8.
  • Primary B-cell lymphoma of the mediastinum is an aggressive non-Hodgkin's lymphoma with distinct clinicopathologic features.
  • Response rates are between 60-80% following intensive chemotherapy regimens.
  • Poor responders or patients with an early relapse usually do not achieve a prolonged second remission with conventional salvage therapy protocols and therefore qualify for intensive or experimental approaches.
  • Here we describe two patients of same age, gender and stage with primary mediastinal B-cell lymphoma and an early relapse after the first courses of combination chemotherapy and irradiation of the mediastinum.
  • One patient relapsed after a salvage therapy with allogeneic donor-related bone marrow transplantation and donor lymphocyte infusion but responded again with a continuing good partial remission after infusion of the chimeric anti-CD20 antibody IDEC-C2B8.
  • He finally failed to respond to salvage therapy with IDEC-C2B8 and died of progressive disease.
  • The anti-CD20 antibody IDEC-C2B8 induced a partial remission in a patient with primary mediastinal B-cell lymphoma refractory to other therapeutic approaches, including allogeneic bone marrow transplanatation (alloBMT), donor lymphocyte infusion (DLI) and irradiation.
  • The role of IDEC-C2B8 as a component of salvage regimens appears to be worthy for further evaluation in high-risk patients with primary mediastinal B-cell lymphoma
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Bone Marrow Transplantation. Lymphoma, B-Cell / therapy. Mediastinal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal, Murine-Derived. Humans. Immunophenotyping. Lymphocyte Transfusion. Male. Recurrence. Rituximab. Salvage Therapy. Transplantation, Isogeneic

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11426614.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


10. Willens HJ, Ahn YS, Gallagher AJ: Evaluation and management of left atrial lymphoma guided by transesophageal echocardiography. Echocardiography; 2003 Aug;20(6):561-2
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation and management of left atrial lymphoma guided by transesophageal echocardiography.
  • A highly mobile left atrial mass was detected by transesophageal echocardiography in a patient with mediastinal lymphoma.
  • Transesophageal echocardiography also demonstrated resolution of the mass following chemotherapy.
  • [MeSH-minor] Adult. Anticoagulants / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Cytarabine / administration & dosage. Cytarabine / therapeutic use. Enoxaparin / therapeutic use. Etoposide / administration & dosage. Etoposide / therapeutic use. Heart Atria. Humans. Male. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / radiotherapy. Methylprednisolone / administration & dosage. Methylprednisolone / therapeutic use

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12859371.001).
  • [ISSN] 0742-2822
  • [Journal-full-title] Echocardiography (Mount Kisco, N.Y.)
  • [ISO-abbreviation] Echocardiography
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Enoxaparin; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone; ESAP protocol
  •  go-up   go-down


11. Anoop P, Lancaster DL, Ethell ME, Potter MN, Wotherspoon A: Relapse of primitive mediastinal lymphoma as a myeloid mass following beam autologous transplant and subsequent refractoriness to matched unrelated umbilical cord blood allograft. Pediatr Hematol Oncol; 2009 Mar;26(2):93-9
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapse of primitive mediastinal lymphoma as a myeloid mass following beam autologous transplant and subsequent refractoriness to matched unrelated umbilical cord blood allograft.
  • Outlining the treatment for an unclassifiable lymphoid malignancy is often difficult.
  • A highly undifferentiated lymphomatous mass that relapsed in spite of intense chemotherapy and autologous transplant is reported.
  • Though remission was achieved with AML-type reinduction chemotherapy, the mass recurred post allogenic cord blood stem cell transplant.
  • [MeSH-major] Cord Blood Stem Cell Transplantation / methods. Lymphoma / pathology. Mediastinal Neoplasms / pathology. Peripheral Blood Stem Cell Transplantation / methods
  • [MeSH-minor] Cell Differentiation. Child. Humans. Male. Myeloid Cells / pathology. Recurrence. Transplantation, Autologous. Transplantation, Homologous. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19322740.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Nagashima O, Takahashi K, Sato K, Suzuki T, Fukuchi Y, Isobe Y, Oshimi K: [Case of malignant lymphoma arising from the posterior mediastinum, with pleural effusion]. Nihon Kokyuki Gakkai Zasshi; 2004 Aug;42(8):772-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of malignant lymphoma arising from the posterior mediastinum, with pleural effusion].
  • We report a rare case of malignant lymphoma arising from the posterior mediastinum with bilateral pleural effusion.
  • A 71-year-old man was admitted to our hospital for evaluation of a posterior mediastinal tumor and bilateral pleural effusion revealed on a chest CT scan.
  • Because no tumor tissue could be obtained by fiberbronchoscopy, video-assisted thoracoscopic surgery was performed.
  • A diagnosis of diffuse large B cell lymphoma was made from the typical histological features.
  • The patient was treated with combination chemotherapy (CHOP) and rituximab and improved dramatically.
  • [MeSH-major] Lymphoma, B-Cell / complications. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / diagnosis. Mediastinal Neoplasms / complications. Mediastinal Neoplasms / diagnosis. Pleural Effusion, Malignant / complications
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / analysis. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Biopsy / methods. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Prednisolone / administration & dosage. Rituximab. Thoracic Surgery, Video-Assisted. Tomography, X-Ray Computed. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15455953.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Biomarkers, Tumor; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  • [Number-of-references] 20
  •  go-up   go-down


13. Noguchi T, Nohara J, Sakaguchi Y, Kono T, Terada Y: [Case of malignant lymphoma associated with rheumatoid arthritis]. Nihon Kokyuki Gakkai Zasshi; 2008 Feb;46(2):131-5
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of malignant lymphoma associated with rheumatoid arthritis].
  • Chest radiograph and chest CT revealed marked mediastinal and right axillary lymph node swelling, interstitial shadows and bilateral pleural effusion.
  • A biopsy of the right axillary lymph node for histopathological examination revealed diffuse large B cell lymphoma.
  • The patient achieved complete remission, following 7 cycles of chemotherapy (R-EPOCH).
  • As RA is associated with an increased risk of developing lymphoma, malignant lymphoma must be considered as a possible cause of the mediastinal swelling in a patient with RA.
  • [MeSH-major] Arthritis, Rheumatoid / complications. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / etiology
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Lymph Nodes / pathology. Lymph Nodes / radiography. Mediastinum. Methotrexate / therapeutic use. Prednisolone / administration & dosage. Remission Induction. Rituximab. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18318257.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


14. Priola AM, Priola SM, Cardinale L, Cataldi A, Fava C: The anterior mediastinum: diseases. Radiol Med; 2006 Apr;111(3):312-42
MedlinePlus Health Information. consumer health - Diagnostic Imaging.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The anterior mediastinum: diseases.
  • Mediastinal tumours are frequently asymptomatic and first noted on routine chest radiograph.
  • In most cases, evaluation should proceed to spiral computed tomography (sCT) of the chest with iodinated contrast material.
  • The specific location and appearance of tumours on sCT is instrumental in planning further diagnostic and treatment strategies.
  • Primary tumours in the anterior mediastinum account for half of all mediastinal masses.
  • They comprise various benign and malignant neoplasms, but a wide variety of nonneoplastic lesions (developmental, inflammatory) can present as a localised mass in this compartment.
  • The most common primary anterior mediastinal tumours are thymoma, teratoma and lymphoma; all other lesions are rare.
  • Understanding the pathology, clinical presentation, imaging and diagnosis of the major tumour types is instrumental in the safe and efficient work-up of a mediastinal mass.
  • Patients with primary mediastinal masses and cysts will usually undergo surgical resection; radiological and clinical features should prompt limited biopsy specimens followed by oncologic consultation, and chemotherapy or radiotherapy when appropriate.
  • The objective of this review was to examine the role of diagnostic imaging in the management of masses of the anterior mediastinum.
  • [MeSH-major] Diagnostic Imaging. Mediastinal Diseases / diagnosis. Mediastinal Neoplasms / diagnosis
  • [MeSH-minor] Contrast Media. Diagnosis, Differential. Humans. Lymphatic Diseases / diagnosis. Mediastinal Cyst / diagnosis. Mediastinitis / diagnosis. Neoplasms, Germ Cell and Embryonal / diagnosis. Thymus Gland / pathology. Tomography, Spiral Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16683081.001).
  • [ISSN] 0033-8362
  • [Journal-full-title] La Radiologia medica
  • [ISO-abbreviation] Radiol Med
  • [Language] eng; ita
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 78
  •  go-up   go-down


15. Deshpande A, Bierman P, Vose J, Bast M, Bociek G, Lynch J, Armitage J: Diffuse large B cell lymphoma with mediastinal mass at presentation. J Clin Oncol; 2004 Jul 15;22(14_suppl):6585

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B cell lymphoma with mediastinal mass at presentation.
  • : 6585 Background: Primary mediastinal B cell lymphoma (PMBL) has been recognized as a subtype of diffuse large B cell lymphoma (DLBCL) with distinct characteristics (e.g.: seen most often in young females) and is thought to be of thymic origin.
  • Other subtypes of DLBCL may involve the mediastinum and may be confused with PMBL.
  • The value of radiotherapy in DLBCL with a mediastinal mass is debated.
  • We conducted this retrospective analysis to study clinical characteristics and treatment outcomes in patients with DLBCL and a mediastinal mass at presentation.
  • METHODS: This is an analysis of 61 patients diagnosed with diffuse large B-cell lymphoma presenting with a mediastinal mass> 5 cms who received their initial treatment between June 1984 and October 2000.
  • 46 % of the patients presented with mediastinal mass >10cms and 69% had B symptoms.
  • 27% received adjuvant radiation therapy.
  • All patients received anthracycline-containing chemotherapy.
  • Patients who received adjuvant radiation therapy compared to those who did not had better EFS (65% vs. 32%, p< 0.01), and OS (72% vs. 45%, p = 0.081).
  • The use of radiation therapy improved outcome in patients with stages I and II and not in III and IV.
  • CONCLUSIONS: Patients with DLBCL with mediastinal mass who present with limited stage disease benefit from adjuvant radiation therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016183.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Suzuki Y, Tokuda Y, Okumura A, Saito Y, Ohta M, Kubota M, Makuuchi H, Tajima T, Umemura S, Osamura RY: Three cases of malignant lymphoma of the breast. Jpn J Clin Oncol; 2000 Jan;30(1):33-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three cases of malignant lymphoma of the breast.
  • We report three cases of malignant lymphoma (ML) of the breast and discuss diagnosis and management.
  • Mastectomy was performed without any adjuvant chemotherapy.
  • Histology revealed diffuse large B-cell lymphoma of REAL classification.
  • Seventy one months after surgery, lesions indicating relapse were detected in nodes of the right axilla, mediastinum and para-aorta.
  • She underwent eight cycles of CHOP regimen, but 1 month after the chemotherapy a brain metastasis was detected.
  • Histology of the tumor revealed diffuse large B-cell lymphoma.
  • The patient underwent eight cycles of CHOP regimen and high-dose chemotherapy (HDC) with peripheral blood stem cell transplantation (PBSCT).
  • Histology of the tumor revealed low-grade B-cell lymphoma of MALT type.
  • Eighteen months after the PBSCT, relapse lesions were detected in nodes of the neck, mediastinum and renal hilum.
  • [MeSH-major] Breast Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Brain Neoplasms / secondary. Chemotherapy, Adjuvant. Cranial Irradiation. Female. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Humans. Lymphatic Metastasis / pathology. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Mastectomy, Extended Radical. Middle Aged. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10770567.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


17. Prêtre R, Turina MI: Temporary one-and-a-half ventricular repair to relieve lymphomatous obstruction of the pulmonary artery. Ann Thorac Surg; 2000 Nov;70(5):1702-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mediastinal lymphoma may infiltrate the conoarterial junction of the heart and cause life-threatening compression of the pulmonary artery.
  • Remission of the tumor after chemotherapy allowed subsequent takedown of the cavopulmonary anastomosis.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Mediastinal Neoplasms / pathology. Pulmonary Artery / pathology. Pulmonary Artery / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11093519.001).
  • [ISSN] 0003-4975
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


18. MacLean FR, Hanley JP, Patton WN, Hart DN, Langley S, Bayston K, Jeffery GM: Successful high dose therapy for relapsed mediastinal large B cell lymphoma following surgical repair of anterior chest wall defect. Clin Lab Haematol; 2000 Apr;22(2):127-8
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful high dose therapy for relapsed mediastinal large B cell lymphoma following surgical repair of anterior chest wall defect.
  • We describe a man with relapsed large B cell mediastinal lymphoma and associated infected large anterior chest wall defect who required high dose salvage therapy for his underlying disease.
  • An initial mediastinotomy wound, associated with recurrent sepsis, had developed into an abscess, then fistula and eventually a large anterior chest wall defect.
  • Safe use of salvage chemotherapy required reconstructive surgery consisting of a pedicled muscle flap.
  • The subsequent high dose chemotherapy was carried out without complications and 15 months later the patient is alive and well.
  • [MeSH-major] Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Mediastinal Neoplasms / drug therapy. Reconstructive Surgical Procedures / methods. Salvage Therapy. Thoracic Surgical Procedures / methods. Thorax / microbiology
  • [MeSH-minor] Abscess / etiology. Abscess / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dose-Response Relationship, Drug. Fistula / etiology. Fistula / surgery. Humans. Male. Middle Aged. Recurrence. Sepsis / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10792407.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


19. Puri V, Meyers BF: Utility of positron emission tomography in the mediastinum: moving beyond lung and esophageal cancer staging. Thorac Surg Clin; 2009 Feb;19(1):7-15
Genetic Alliance. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of positron emission tomography in the mediastinum: moving beyond lung and esophageal cancer staging.
  • In the mediastinum, PET can provide information to distinguish thymic hyperplasia from neoplasia, although the use of this imaging for this purpose is not accepted uniformly as necessary.
  • PET is the standard of care in staging and follow-up of mediastinal lymphoma and in follow-up of metastatic seminomas after chemotherapy.
  • Mycobacterial/fungal infections, sarcoidosis, and brown fat can mimic malignant findings on PET in the mediastinum.
  • [MeSH-major] Mediastinum / radionuclide imaging. Positron-Emission Tomography. Thoracic Neoplasms / radionuclide imaging
  • [MeSH-minor] Fluorodeoxyglucose F18. Humans. Lymphoma / pathology. Lymphoma / radionuclide imaging. Neoplasm Staging. Parathyroid Neoplasms / pathology. Parathyroid Neoplasms / radionuclide imaging. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19288816.001).
  • [ISSN] 1547-4127
  • [Journal-full-title] Thoracic surgery clinics
  • [ISO-abbreviation] Thorac Surg Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 34
  •  go-up   go-down


20. Cracco C, Divine M, Maitre B: [Thoracic involvement in Hodgkin's lymphoma]. Rev Mal Respir; 2007 Oct;24(8):999-1012
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thoracic involvement in Hodgkin's lymphoma].
  • [Transliterated title] Atteintes thoraciques au cours des lymphomes hodgkiniens.
  • INTRODUCTION: Hodgkin's lymphoma is defined by a malignant prolifération of Reed-Sternberg or Hodgkin cells that are clonally related B-cell-derived malignant cells.
  • Initial thoracic involvement is usual and the more frequent localization is the mediastinum, following by the lung parenchyma and the pleura.
  • In the last two cases, histological diagnosis is warranted since this involvement modified the staging and the prognosis of the disease.
  • Functional deficiency following mediastinal radiotherapy and chemotherapy (including bleomycin) is often detected, whatever this is associated with symptom or CT scan abnormalities.
  • Granulomatous disease can be associated at any time during the disease and differential diagnosis from relapse is often difficult.
  • PERSPECTIVES AND CONCLUSIONS: Hodgkin lymphoma patients are more likely to die from acute and late treatment-related toxicities and the major task is to reduce treatment associated toxicity while maintaining cure rate.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / therapy. Thoracic Neoplasms / diagnosis. Thoracic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18033187.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 73
  •  go-up   go-down


21. Bagshaw SM, Crabtree T, Green F, Stewart DA: ALK-positive anaplastic large T-cell lymphoma preceded by Epstein-Barr virus infection complicated by development of an aorto-esophageal fistula. Leuk Lymphoma; 2002 Apr;43(4):915-8
Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive anaplastic large T-cell lymphoma preceded by Epstein-Barr virus infection complicated by development of an aorto-esophageal fistula.
  • We report an unusual case of aggressive ALK-positive anaplastic large cell lymphoma with widespread mediastinal involvement immediately preceded by an acute Epstein-Barr virus (EBV) infection.
  • Following initiation of chemotherapy and radiological evidence of significant tumor regression, the patient suffered a fatal massive upper gastrointestinal hemorrhage from an aorto-esophageal fistula.
  • The relevant literature relating to EBV in the pathogenesis of ALK-lymphomas and literature relating to aorto-enteric fistula (AEF) in mediastinal lymphoma is reviewed.
  • [MeSH-major] Aortic Diseases / etiology. Epstein-Barr Virus Infections / complications. Esophageal Fistula / etiology. Lymphoma, Large B-Cell, Diffuse / etiology. Lymphoma, T-Cell / etiology. Protein-Tyrosine Kinases / analysis. Vascular Fistula / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12153187.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


22. Konety SH, Wooldridge JE, Kerber RE: Primary cardiac non-Hodgkin's lymphoma diagnosed by transthoracic echocardiography. Echocardiography; 2006 Feb;23(2):147-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cardiac non-Hodgkin's lymphoma diagnosed by transthoracic echocardiography.
  • Primary cardiac lymphomas are extremely rare and can be diagnosed by echocardiography.
  • We present the case of a 79-year-old man with an intracardiac mass, shown to be an aggressive large B-cell lymphoma by mediastinal aspiration, who had rapid regression of the tumor following one cycle of chemotherapy.
  • [MeSH-major] Heart Neoplasms / ultrasonography. Lymphoma, Non-Hodgkin / ultrasonography
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445735.001).
  • [ISSN] 0742-2822
  • [Journal-full-title] Echocardiography (Mount Kisco, N.Y.)
  • [ISO-abbreviation] Echocardiography
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Tsai MH, Yang CP, Chung HT, Shih LY: Acute myeloid leukemia in a young girl presenting with mediastinal granulocytic sarcoma invading pericardium and causing superior vena cava syndrome. J Pediatr Hematol Oncol; 2009 Dec;31(12):980-2
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia in a young girl presenting with mediastinal granulocytic sarcoma invading pericardium and causing superior vena cava syndrome.
  • A 1-year-4-month-old girl who presented with pericardial effusion and superior vena cava (SVC) syndrome caused by a mediastinal mass was later proved to be a case of acute myeloid leukemia (AML) with mixed-lineage leukemia-gene translocation.
  • The unusual presentation and the giant blasts with basophilic vacuolated cytoplasm had led to initial misdiagnosis of mediastinal lymphoma.
  • She developed progressive SVC syndrome, unresolved pericardial effusion, and extensive leukemia cutis after initial induction therapy.
  • She died soon after second-course chemotherapy.
  • To our knowledge, this is the first reported case of childhood acute myeloid leukemia presenting with mediastinal granulocytic sarcoma causing pericardium invasion and SVC syndrome.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Mediastinal Neoplasms / diagnosis. Pericardium / pathology. Sarcoma, Myeloid / diagnosis. Superior Vena Cava Syndrome / diagnosis
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Diagnosis, Differential. Fatal Outcome. Female. Humans. Infant. Pericardial Effusion / etiology


24. Tanaka J, Takamoto S, Ryu T, Ichikawa K, Masuo M, Saito T: [Primary cardiac lymphoma: a case report]. J Cardiol; 2002 Nov;40(5):225-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary cardiac lymphoma: a case report].
  • Transvenous biopsy failed to obtain sufficient specimens for the histological diagnosis.
  • The diagnosis was primary cardiac lymphoma on the basis of elevated soluble interleukin-2 receptor and solitary accumulation of gallium-67 in the heart.
  • Chemotherapy was immediately started.
  • After two courses of chemotherapy, the intracardiac tumor disappeared.
  • However, one month later, the tumor relapsed in the anterior mediastinum.
  • Needle biopsy disclosed diffuse B-cell non-Hodgkin's malignant lymphoma.
  • Early diagnosis and immediate chemotherapy are important for the treatment of primary cardiac lymphoma.
  • [MeSH-major] Heart Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12463097.001).
  • [ISSN] 0914-5087
  • [Journal-full-title] Journal of cardiology
  • [ISO-abbreviation] J Cardiol
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Gallium Radioisotopes; 0 / Receptors, Interleukin-2
  •  go-up   go-down


25. Schneider T, Tóth E, Molnár Z, Várady E, Deák B, Horváth A, Horváth GI, Eid H, Schneider K, Lovey J, Keresztes S, Esik O, Lengyel Z, Rosta A: [Treatment of primary mediastinal large B-cell lymphomas]. Orv Hetil; 2004 Dec 12;145(50):2531-7
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of primary mediastinal large B-cell lymphomas].
  • INTRODUCTION: Primary mediastinal large B-cell non-Hodgkin's lymphoma is a relatively rare disease with specific clinical symptoms.
  • This tumour originates from a subset of B-cells of the thymus and at the time of the diagnosis the disease is predominantly localised in the mediastinum.
  • This is the only lymphoma subtype which can only be defined by the combination of clinical and pathologic features.
  • Analysis with DNA microarrays verified that primary mediastinal and diffuse large B-cell lymphomas are different diseases.
  • AIMS: Comparing the effectiveness of two types of anthracycline-based standard chemotherapy regimens and the evaluation of the prognostic markers which are applied in large B-cell lymphomas.
  • METHODS: 27 patients with primary mediastinal lymphoma were treated by the authors with anthracycline-based polychemotherapy with complementary radiotherapy from January 1995 to December 2002.
  • 9 additional patients (33%) achieved partial remission, while in 3 cases (11%) the treatment was ineffective.
  • The patients who failed to achieve complete remission were subsequently treated with more intensive chemotherapy.
  • Afterwards, those patients who were chemosensitive, underwent high-dose chemotherapy with autologous peripheral blood stem-cell transplantation.
  • The chemoresistant patients received palliative chemotherapy.
  • CONCLUSION: The authors found that the procarbazine, prednisolone, adriamycin, cyclophosphamide, etoposide, cytosine-arabinoside, bleomycin, vincristine, methotrexate treatment was more effective than the cyclophosphamide, adriamycin, vincristine, prednisolone combination.
  • The results with the new standard of combined immuno-chemotherapy (rituximab--cyclophosphamide, adriamycin, vincristine, prednisolone) seem to be hopeful and more effective than earlier treatments.
  • [MeSH-major] Anthracyclines / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Mediastinal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Peripheral Blood Stem Cell Transplantation. Prednisolone / administration & dosage. Procarbazine / administration & dosage. Prognosis. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15662753.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Biomarkers, Tumor; 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


26. Tanigawa M, Ishiga T, Ichioka M, Saito K: [A case of CD56 positive T-cell lymphoma originating from mediastinal lymph nodes]. Nihon Kokyuki Gakkai Zasshi; 2006 Dec;44(12):944-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of CD56 positive T-cell lymphoma originating from mediastinal lymph nodes].
  • The chest CT scan revealed left mediastinal enlargement.
  • His general condition worsened in spite of anti-tuberculosis therapy and soluble interleukin-2 receptor (sIL-2R) was elevated.
  • Soon after that the lymph nodes from the left supraclavicular region to the mediastinum became swollen.
  • The diagnosis of peripheral T-cell lymphoma, unspecified (WHO classification) with CD56 expression, was established based on the results of lymph node biopsy and pleural effusion cytology.
  • He was treated with cyclophosphamide/doxorubicin/vincristine/prednisolone (CHOP) chemotherapy.
  • Since two courses of chemotherapy were not effective we changed to carboplatin/ifosfamide/ etoposide/dexamethasone (DeVIC) chemotherapy.
  • In conclusion, the presence of a high level of ADA in the pleural effusion and resistance to anti-tuberculosis therapy should suggest a malignant lymphoma.
  • [MeSH-major] Antigens, CD56 / analysis. Lymph Nodes / pathology. Lymphoma, T-Cell / immunology. Mediastinal Neoplasms / immunology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Pleural Effusion, Malignant / diagnosis. Prednisolone / administration & dosage. Tuberculosis, Pleural / diagnosis. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17233392.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD56; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide; ICE protocol 2; VAP-cyclo protocol
  •  go-up   go-down


27. Wobser R, Wilpert J, Kayser G, Walz G, Stubanus M: [Disseminated histoplasmosis with involvement of mediastinum and skin in an immunocompetent patient]. Dtsch Med Wochenschr; 2009 Mar;134(12):589-93
Hazardous Substances Data Bank. Itraconazole .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Disseminated histoplasmosis with involvement of mediastinum and skin in an immunocompetent patient].
  • [Transliterated title] Disseminierte Histoplasmose mit Befall des Mediastinums und der Haut bei immunkompetenter Patientin.
  • Radiology showed an enlargement of the upper mediastinum.
  • Computed tomography revealed extensive, confluent lymphoma.
  • DIAGNOSIS: Bronchial biopsy revealed necrotizing, granulomatous inflammation with dense infiltration of lymphatic cells.
  • TREATMENT AND COURSE: 8 weeks after starting specific treatment with oral itraconazole the inflammatory parameters had fallen to normal and computed tomography showed regression of the mediastinal bulge.
  • CONCLUSION: Large mediastinal and cervical lymphatic masses with space-occupying bronchial lesions suggest should, in the differential diagnosis, consider not only malignant tumor but also infections.
  • In this immunocompetent patient the severe progression and dissemination of the disease, involving mediastinum, throat and skin, is most unusual.
  • [MeSH-major] Antifungal Agents / therapeutic use. Histoplasmosis / diagnosis. Histoplasmosis / drug therapy. Itraconazole / therapeutic use. Mediastinum / pathology. Skin / pathology
  • [MeSH-minor] Adult. Bronchi / parasitology. Bronchi / pathology. Female. Histoplasma / isolation & purification. Humans. Inflammation / drug therapy. Inflammation / microbiology. Necrosis

  • MedlinePlus Health Information. consumer health - Histoplasmosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19277935.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antifungal Agents; 304NUG5GF4 / Itraconazole
  •  go-up   go-down


28. Uppin MS, Paul TR, Rajappa S, Gayathri K, Jacob R, Uppin SG: Leukemia as a second malignancy. Indian J Pathol Microbiol; 2007 Jul;50(3):644-7
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To study the occurrence of leukemia as a second malignancy following various primary solid and hematological malignancies.
  • The primary malignancies included carcinoma breast (4), multiple myeloma (3) and one each of Hodgkin's lymphoma, mediastinal germ cell tumor, papillary carcinoma thyroid and myxopapillary ependymoma.
  • Ten patients had received chemotherapy with combination radiotherapy in six patients.
  • The commonest type of leukemia was AML-M2.
  • The risk benefit ratio of chemotherapy and radiotherapy should be considered before starting the patients on treatment.
  • A high degree of suspicion and follow up with hematological parameters is required for therapy related complications.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Leukemia, Myeloid, Acute. Neoplasms, Second Primary. Radiotherapy / adverse effects
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883171.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


29. Maisch B, Ristic A, Pankuweit S: Evaluation and management of pericardial effusion in patients with neoplastic disease. Prog Cardiovasc Dis; 2010 Sep-Oct;53(2):157-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a considerable number of patients with breast or lung cancer or with mediastinal lymphoma, in addition to direct involvement by the tumor, radiation therapy as well as systemic tumor treatment can also lead to pericardial effusion.
  • To distinguish between these 3 different conditions leading to pericardial effusion, the diagnosis should be based on pericardiocentesis followed by fluid analysis for cytology and biomarkers, on epicardial and pericardial biopsy facilitated by flexible pericardioscopy with analysis of specimens by conventional histology and molecular biology techniques for viral and microbial aetiology.
  • With these methods, 42 patients demonstrated malignant effusion, 15 patients had radiation-induced pericardial, effusion, and in 11 patients without radiation therapy, the effusion could be attributed to either viral infection in 5 cases or to an autoimmune process in the remaining 6 patients.
  • Consequently, intrapericardial treatment could be tailored for each cohort: neoplastic effusion was treated with intrapericardial cisplatin (single instillation of 30 mg/m(2) per 24 hours); in addition to the tumor-specific systemic chemotherapy, intrapericardial triamcinolone acetate (Volon A) was given in a dose of 500 mg/m(2) in the patients with autoimmune and radiation-induced effusion.
  • Saline rinsing and intrapericardial sclerosing treatment were the treatment of choice in viral pericardial effusion.
  • Oral colchicine treatment (2-3 x 0.5 mg) was given in all patients for at least 3 months.
  • This differential diagnostic approach and the results of treatment were compared with published series.
  • [MeSH-major] Neoplasms / therapy. Pericardial Effusion / diagnosis. Pericardial Effusion / therapy. Radiation Injuries / diagnosis. Radiation Injuries / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Bacterial Infections / complications. Biomarkers / analysis. Biopsy. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Pericardiocentesis. Polymerase Chain Reaction. Predictive Value of Tests. Radiotherapy / adverse effects. Recurrence. Registries. Retrospective Studies. Risk Assessment. Risk Factors. Time Factors. Treatment Outcome. Virus Diseases / complications

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20728703.001).
  • [ISSN] 1873-1740
  • [Journal-full-title] Progress in cardiovascular diseases
  • [ISO-abbreviation] Prog Cardiovasc Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers
  •  go-up   go-down


30. Petersdorf SH, Wood DE: Lymphoproliferative disorders presenting as mediastinal neoplasms. Semin Thorac Cardiovasc Surg; 2000 Oct;12(4):290-300
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoproliferative disorders presenting as mediastinal neoplasms.
  • The mediastinum is an uncommon location for presentation of these heterogeneous disorders, but involvement of the mediastinum may be the sole site of disease for several aggressive lymphomas.
  • Both Hodgkin's disease and non-Hodgkin's lymphoma may present in the mediastinum.
  • The most common types of non-Hodgkin's lymphoma involving the mediastinum include lymphoblastic lymphoma and mediastinal large cell lymphoma.
  • These lymphomas most commonly develop in the anterior mediastinum but may be seen in the middle and posterior mediastinum.
  • Symptoms associated with a mediastinal presentation of a lymphoproliferative disorder are often attributable to compression of mediastinal structures (eg, superior vena cava syndrome) or invasion of thoracic structures such as the pericardium or pleura.
  • Although staging can be performed with routine imaging studies, surgical intervention is often required to ensure accurate histologic diagnosis of these lymphomas.
  • Once a diagnosis has been established, therapeutic modalities usually include chemotherapy and/or radiotherapy.
  • [MeSH-major] Lymphoma. Mediastinal Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 by W.B. Saunders Company
  • (PMID = 11154724.001).
  • [ISSN] 1043-0679
  • [Journal-full-title] Seminars in thoracic and cardiovascular surgery
  • [ISO-abbreviation] Semin. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 41
  •  go-up   go-down


31. Nguyen LN, Ha CS, Hess M, Romaguera JE, Manning JT, Cabanillas F, Cox JD: The outcome of combined-modality treatments for stage I and II primary large B-cell lymphoma of the mediastinum. Int J Radiat Oncol Biol Phys; 2000 Jul 15;47(5):1281-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The outcome of combined-modality treatments for stage I and II primary large B-cell lymphoma of the mediastinum.
  • PURPOSE: Primary mediastinal large B-cell lymphoma (PML) has clinicopathologic features distinct from those of other diffuse large-cell lymphomas.
  • However, the optimal treatment for this tumor is evolving, and in particular, the role of radiation therapy remains undefined.
  • We conducted a retrospective review to evaluate the role of radiation therapy in this disease.
  • All patients were treated with doxorubicin-based chemotherapy, and 35 patients received radiation therapy.
  • For most patients who received radiation therapy, an involved field or a modified-mantle field was used, and a dose of 40 Gy in 20 fractions or 39.6 Gy in 22 fractions was administered.
  • Thirty-five patients achieved a complete response; 32 of these patients received radiation therapy.
  • Only 2 of the 5 completed the planned course of radiation therapy; both had massive mediastinal disease.
  • There was no treatment-related death from the initial chemotherapy or radiation therapy.
  • One patient developed a second malignancy (sarcoma) within the radiation field after 13 years.
  • CONCLUSION: We recommend consolidative radiation therapy in view of the excellent local control and the lack of significant toxicity.
  • Modified mantle or involved field appears to be an adequate volume, and 39.6-40 Gy appears to be an adequate dose.
  • [MeSH-major] Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / radiotherapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Analysis of Variance. Combined Modality Therapy. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Neoplasm Staging. Recurrence. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10889382.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


32. Yang GC, Yee HT, Wu CD, Aye LM, Chachoua A: TIA-1+ cytotoxic large T-cell lymphoma of the mediastinum: case report. Diagn Cytopathol; 2002 Mar;26(3):154-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TIA-1+ cytotoxic large T-cell lymphoma of the mediastinum: case report.
  • A 52-year-old previously healthy Caucasian woman presented with superior vena cava syndrome, secondary to compression of a bulky anterior mediastinal mass involving the right lung.
  • Fine-needle aspiration biopsy of the mediastinum yielded large epithelioid cells intermingled with small mature lymphocytes.
  • The patient responded well to six cycles of CHOP chemotherapy, followed by radiation with a total dose of 4140 cGy delivered to the mediastinum in 23 fractions.
  • To the best of our knowledge, this case may be the first report of cytotoxic large T-cell lymphoma of the mediastinum.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, T-Cell, Peripheral / pathology. Mediastinal Neoplasms / pathology. Membrane Proteins / biosynthesis. Proteins. RNA-Binding Proteins / biosynthesis. T-Lymphocytes, Cytotoxic / pathology

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 11892019.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Poly(A)-Binding Proteins; 0 / Proteins; 0 / RNA-Binding Proteins; 0 / TIA1 protein, human
  •  go-up   go-down


33. Lerza R, Botta M, Barsotti B, Schenone E, Mencoboni M, Bogliolo G, Pannacciulli I, Arboscello E: Dexamethazone-induced acute tumor lysis syndrome in a T-cell malignant lymphoma. Leuk Lymphoma; 2002 May;43(5):1129-32
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dexamethazone-induced acute tumor lysis syndrome in a T-cell malignant lymphoma.
  • A 60-year-old woman was started on steroid therapy for dyspnea due to bilateral pleural effusion and a large mass involving the anterior mediastinum.
  • The final diagnosis was precursor T-lymphoblastic lymphoma-leukemia.
  • Following steroid therapy, the patient developed acute renal failure and laboratory evidence of metabolic changes induced by massive cytolysis.
  • She received vigorous hydration, diuretic and allopurinol therapy, and haemodialysis.
  • A review of the medical literature on T-cell lymphoma revealed only one similar case of steroid-induced acute tumor lysis syndrome, a life-threatening metabolic emergency.
  • [MeSH-major] Dexamethasone / adverse effects. Lymphoma, T-Cell / drug therapy. Tumor Lysis Syndrome / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12148896.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


34. Hartmann S, Hansmann ML: [Grayzone lymphoma. Clinical relevance]. Pathologe; 2010 Feb;31(1):42-9
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Grayzone lymphoma. Clinical relevance].
  • Malignant lymphomas are classified into different entities according to their morphology, immunohistochemical parameters and clinical behavior.
  • Several important pathogenetic events can be assigned to certain lymphoma entity types.
  • Nevertheless, some cases present overlapping morphologic and immunohistochemical characteristics and a clear-cut diagnosis cannot be made.
  • This is particularly the case with aggressive lymphomas for which a clear distinction cannot be made between the entities of diffuse large cell lymphoma/Burkitt lymphoma or primary mediastinal B cell lymphoma/classic Hodgkin's lymphoma.
  • Until further knowledge regarding the therapy, behavior and prognosis of these gray zone lymphomas has been gained, they should continue to be considered as distinct entities.
  • [MeSH-major] Lymphoma / classification. Lymphoma / pathology
  • [MeSH-minor] Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. B-Lymphocytes / pathology. Biomarkers, Tumor / genetics. Burkitt Lymphoma / classification. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / genetics. Burkitt Lymphoma / pathology. DNA Mutational Analysis. Diagnosis, Differential. Hodgkin Disease / classification. Hodgkin Disease / drug therapy. Hodgkin Disease / genetics. Hodgkin Disease / pathology. Humans. Immunoenzyme Techniques. Lymphoma, B-Cell / classification. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / classification. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Mediastinal Neoplasms / classification. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / genetics. Mediastinal Neoplasms / pathology. Molecular Diagnostic Techniques. Rituximab. T-Lymphocytes / pathology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 1989 Mar;9(3):1165-72 [2566907.001]
  • [Cites] N Engl J Med. 2009 Sep 3;361(10):958-67 [19692684.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1523-9 [18441328.001]
  • [Cites] J Clin Oncol. 2009 Nov 20;27(33):5573-9 [19786664.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4930-5 [17299093.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):141-51 [16645199.001]
  • [Cites] J Exp Med. 2008 Sep 29;205(10):2251-68 [18794340.001]
  • [Cites] Clin Cancer Res. 2009 Sep 1;15(17):5494-502 [19706817.001]
  • [Cites] J Pathol. 2008 Dec;216(4):440-50 [18802929.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):243-53 [12507907.001]
  • [Cites] Leukemia. 2007 Apr;21(4):780-7 [17375124.001]
  • [Cites] J Hematop. 2009 Jul;2(2):89-95 [19669187.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4340-6 [16908931.001]
  • [Cites] N Engl J Med. 2008 Nov 27;359(22):2313-23 [19038878.001]
  • [Cites] Haematologica. 2008 Sep;93(9):1318-26 [18641027.001]
  • [Cites] Oncogene. 2006 Apr 27;25(18):2679-84 [16532038.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3387-90 [17652621.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1411-21 [16224207.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10962-6 [7971992.001]
  • [Cites] Lancet Oncol. 2002 Apr;3(4):229-34 [12067685.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):294-301 [16848772.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] Lancet Oncol. 2005 Apr;6(4):249-51 [15811621.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1335-42 [18024371.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1571-8 [8608249.001]
  • [Cites] Blood. 2009 Nov 12;114(20):4503-6 [19734449.001]
  • [Cites] N Engl J Med. 1999 Nov 11;341(20):1520-9 [10559454.001]
  • [Cites] J Exp Med. 2009 May 11;206(5):981-9 [19380639.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):489-95 [12478664.001]
  • [Cites] Leukemia. 2008 Dec;22(12):2226-9 [18754028.001]
  • [Cites] Stem Cells. 1998;16(6):413-28 [9831867.001]
  • [Cites] Blood. 2009 Oct 22;114(17):3533-7 [19704118.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2535-42 [15572583.001]
  • (PMID = 20013122.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 37
  •  go-up   go-down


35. Matsubayashi T, Ohro Y, Yagyuu T, Miyahara J: Coexistence of T-cell lymphoblastic lymphoma and myelodysplastic syndrome in a child. J Pediatr Hematol Oncol; 2008 Sep;30(9):701-3
MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of T-cell lymphoblastic lymphoma and myelodysplastic syndrome in a child.
  • A 10-year-old girl presented with T-cell lymphoblastic lymphoma of the mediastinum coexisting with myelodysplastic syndrome.
  • Bone marrow examination showed trilineage dysplasia with no evidence of lymphoma cells.
  • Intensive chemotherapy led to a marked reduction in the mediastinal tumor, but no improvement in bone marrow findings.
  • A possible explanation for the simultaneous presentation of T-cell lymphoblastic lymphoma and myelodysplastic syndrome is that transformation occurs in pluripotent stem cells differentiating into myeloid and lymphoid cells.
  • [MeSH-major] Lymphoma, T-Cell / complications. Mediastinal Neoplasms / complications. Myelodysplastic Syndromes / complications


36. Sorgho-Lougue LC, Luciani A, Kobeiter H, Zelek L, Malhaire C, Deux JF, Brun B, Piedbois P, Rahmouni A: Adenocarcinomas of unknown primary (ACUP) of the mediastinum mimicking lymphoma: CT findings at diagnosis and follow-up. Eur J Radiol; 2006 Jul;59(1):42-8
Genetic Alliance. consumer health - Diagnosis Unknown.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinomas of unknown primary (ACUP) of the mediastinum mimicking lymphoma: CT findings at diagnosis and follow-up.
  • OBJECTIVE: To describe the computed tomography (CT) features at diagnosis and after treatment of adenocarcinoma of unknown primary (ACUP) mimicking lymphoma of the mediastinum.
  • METHODS: Fifteen patients with pathologically proven ACUP and with primarily mediastinal involvement were initially referred to the Hematologic Department of our institution with a suspected diagnosis of lymphoma, and accounted for our study population.
  • All thoraco-abdominal CT studies were reviewed for the location and size of the mediastinal involvement and associated findings.
  • Follow-up chest CT was performed in 14 patients after radiotherapy, chemotherapy or surgical treatment.
  • RESULTS: The most frequent CT feature was a large anterior and middle mediastinal mass (67%), with no calcification.
  • Associated findings included the presence of lung nodules (40%), compression of large mediastinal vessels (33%) and pleural effusion (27%).
  • Follow-up CT, performed in 14 cases, suggested partial or complete responses in 7 patients (50%) 4 weeks after the treatment onset.
  • CONCLUSIONS: Mediastinal ACUP is a differential diagnosis of large mediastinal masses and is frequently associated with lung nodules and mediastinal vascular compression.
  • [MeSH-major] Adenocarcinoma / radiography. Adenocarcinoma / secondary. Mediastinal Neoplasms / radiography. Mediastinal Neoplasms / secondary. Neoplasms, Unknown Primary / radiography. Tomography, Spiral Computed
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Lymphoma / radiography. Male. Middle Aged. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16504446.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


37. Christodoulou M, Ris HB, Pezzetta E: Video-assisted right supradiaphragmatic thoracic duct ligation for non-traumatic recurrent chylothorax. Eur J Cardiothorac Surg; 2006 May;29(5):810-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Surgical management is indicated in case of recurrence or failure after conservative treatment.
  • Three patients developed chylothorax after chemotherapy and chest irradiation for malignant diseases (lymphoma in two patients and breast cancer in one), one in the context of lymphangioleiomyomatosis, one due to a non-diagnosed lymphoma, and one after heart transplantation.
  • RESULTS: The mean operative time was 102 min, with an average length of hospital stay of 14 days.
  • Persistent cessation of chylous effusion within 7 days after surgery was observed in 5/6 patients without recurrence during a mean follow-up time of 41 months.
  • One patient with undiagnosed mediastinal lymphoma required re-operation and thoracic duct ligation on day 8 by right-sided thoracotomy due to persistent chylothorax.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cardiothorac Surg. 2006 Nov;30(5):813 [16996746.001]
  • [CommentIn] Eur J Cardiothorac Surg. 2007 Jun;31(6):1148-9; author reply 1149 [17398111.001]
  • (PMID = 16626966.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement